89bio stock (US28252C1099): Delisting amid liquidation process

89bio Inc (ETNB) common stock has been delisted pending stock liquidation, as noted by Robinhood's corporate actions tracker. This development impacts US investors holding shares in the clinical-stage biotech.

89bio Inc, a clinical-stage biopharmaceutical company, saw its common stock (ETNB) delisted pending a stock liquidation process. The update appears in Robinhood's corporate actions tracker, signaling potential closure for shareholders. Details on the liquidation remain pending as of the latest available information.

The stock traded on Nasdaq under the ticker ETNB prior to delisting. 89bio focused on developing therapies for liver diseases, including non-alcoholic steatohepatitis (NASH). This event follows typical paths for biotechs facing challenges in clinical trials or funding, affecting retail investors in the US biotech sector.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: 89bio Inc
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Liver disease therapies
• Home exchange/listing venue: Nasdaq (ETNB, delisted)

89bio: core business model

89bio Inc developed innovative therapies targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, and other liver conditions. The company's lead candidate, pegozafermin, advanced through clinical trials aimed at fibrosis and metabolic improvements. US investors followed its pipeline for potential breakthroughs in a high-need area of hepatology.

Main revenue and product drivers for 89bio

As a pre-revenue biotech, 89bio relied on funding from equity raises and partnerships to drive R&D. Key focus was on FGF21 analogs like pegozafermin, tested in Phase 2b trials for MASH. The company reported progress in studies such as ENLIGHTEN-Fibrosis, though commercialization remained distant. Revenue potential hinged on regulatory approvals, relevant for US markets with rising liver disease prevalence.

Conclusion

The delisting of 89bio stock pending liquidation marks a significant event for shareholders. While the company pursued promising liver disease treatments, this development shifts focus to liquidation outcomes. US investors should monitor official channels for updates on asset distribution and any remaining value.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.